Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
about
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyAdvances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesComparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?Myeloablative conditioning regimens for AML allografts: 30 years later.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsPretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.Biology and management of relapsed acute myeloid leukaemia.Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Emerging drugs for the treatment of myelodysplastic syndrome.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Changing the treatment paradigm in myelodysplastic syndromes.Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.NKT cells, Treg, and their interactions in bone marrow transplantation.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence.The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children.Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.
P2860
Q27010653-A963DB02-24FC-41B8-BA0C-B0AD0DE06184Q27014857-F9EE2344-213E-4F38-9BDE-E513E0258F8DQ30675919-E4E28AAA-F0AB-4DD2-97F1-0E085AA1C4ACQ33771667-FC98D83C-29AD-4D51-81C3-D918D1977133Q34185528-EB5BAFF4-7F84-44ED-B591-45235A61DA49Q34348102-7F415424-7633-4B86-8B6D-3BCD1A98BBEFQ35100141-5B264559-889C-4B63-8670-75F310808C2BQ35196663-9FFBE475-9347-47AC-8B72-1BCA9FF145DAQ35202588-F4BD005F-04C4-48F6-9783-D9BFB61F8B34Q35574536-9900FFEC-B70A-44F2-9D4F-7180FA084FDEQ35800814-20CB1DCB-1241-4BAE-BB5E-A6D79DB2FF4DQ35838113-6CE3F8B9-0966-436E-9595-A133483B0969Q36036263-7CD0C0DE-8359-4F07-B3CB-49B10509AFFEQ36085026-B1C959C9-CEEE-4CDE-87C4-95135E73B7C5Q36182976-44900F05-0A8B-49CA-85E5-7D9706E96328Q36219655-07934958-C2FE-462D-8304-674077FADDC9Q36484688-4057F71D-3703-4FB0-A799-058C02DBFD30Q36548362-59175FF9-CFF5-4E45-A200-E5B6F9391D25Q36548370-F195599E-CE7B-4131-B22D-082FD27BC678Q37061969-528B8DF8-0A0F-4358-A256-61A237D224DEQ37159533-BC18505F-3CF6-4541-9834-833B89F67E6FQ37263146-64CE17D1-273A-4AD3-9D6C-9BA83847C31BQ37277994-052858C7-8B22-41E4-83C0-AA8BBAE04D56Q37419348-53D26EF3-111E-404C-AAB9-358442895E42Q37681792-E90B18DE-A9EF-41A5-B63A-DA2506064F8AQ37768104-0FD937EE-A610-426A-8861-B549D492553BQ37810098-A4DB5DAB-11B9-4BD9-9F60-0C53BD8B9E18Q38852431-74C8F24F-10E2-422B-84D7-C87F06A498A9Q39282540-2F193711-6401-4C9D-9C2A-2E98512A9CABQ40438036-9E445156-21C9-45B0-9C89-FCF15FEC634FQ42152223-94BAFDFC-3C0E-4AB6-9DFB-2EFAB578A595Q44043143-5E3045DE-8ADF-4D91-8CE5-4654166D8D70Q44282612-4776D620-2CF9-47B5-ABFF-692CA1333753Q44386867-21449764-1EE6-4DB5-93BE-0A821A3ADFF9Q44499717-B57C7F64-343F-48FE-A16A-C46B12F9FDF0Q46543507-20873F09-C67D-4A50-9BCB-46A4F444E704Q46608663-F4ABE749-FC55-4986-B86D-E15310CD6540Q46819255-14E4A1A7-06A6-4BF4-85E2-A1715E1E3631Q46896197-BFD49F95-0B57-49E2-B74A-DB409AA9B237Q47144269-55FF7DE7-6FCB-4A4D-A64F-3B0E84E6A80C
P2860
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@en
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@nl
type
label
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@en
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@nl
prefLabel
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@en
Evidence for a graft-versus-le ...... and myelodysplastic syndromes.
@nl
P2093
P1433
P1476
Evidence for a graft-versus-le ...... and myelodysplastic syndromes
@en
P2093
AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation
Alvaro Urbano-Ispízua
Angel Léon
Carlos Solano
Carmen Canals
Joan Bargay
Jorge Sierra
Josep Sarrá
José Antonio Pérez-Simón
José María Moraleda
P304
P356
10.1182/BLOOD-2002-02-0400
P407
P577
2002-09-01T00:00:00Z